SCHEMBL2525011

SCHEMBL2525011

COc1nccc(-c2cc(-c3c[nH]c4ncccc34)cc(OC(C)(C)C)n2)c1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.47
DYRK1A Q13627 10/20 0.47
CDC7 O00311 14/20 0.46
PRKACA P17612 14/20 0.46
PIM1 P11309 13/20 0.46
ROCK2 O75116 13/20 0.46
CDK2 P24941 13/20 0.46
HIPK2 Q9H2X6 13/20 0.46
GSK3B P49841 12/20 0.46
CLK4 Q9HAZ1 10/20 0.46
IRAK4 Q9NWZ3 8/20 0.46
MAP4K4 O95819 9/20 0.45
CDK7 P50613 9/20 0.45
CDK9 P50750 9/20 0.45
DAPK3 O43293 7/20 0.45
CLK2 P49760 7/20 0.45
PRKX P51817 7/20 0.45
CDK5 Q00535 7/20 0.45
PRKD3 O94806 6/20 0.45
PAK4 O96013 6/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2533349 0.81 BRD4 (0.53) BRD4DYRK1ACDC7PRKACAPIM1
SCHEMBL2534550 0.81 BRD4 (0.50) BRD4DYRK1ACDC7PRKACAPIM1
SCHEMBL2534178 0.81 CDC7 (0.63) BRD4DYRK1ACDC7PRKACAPIM1
SCHEMBL2534175 0.81 DYRK1A (0.51) BRD4DYRK1ACDC7PRKACAPIM1
SCHEMBL2528281 0.80 DYRK1A (0.46) BRD4DYRK1ACDC7PRKACAPIM1
SCHEMBL2574446 0.80 BRD4 (0.48) BRD4DYRK1ACDC7PRKACAPIM1
SCHEMBL28805250 0.79 DYRK1A (0.49) BRD4DYRK1ACDC7PRKACAPIM1
SCHEMBL2528668 0.79 DYRK1A (0.49) BRD4DYRK1ACDC7PRKACAPIM1
SCHEMBL2531171 0.78 BRD4 (0.51) BRD4DYRK1ACDC7PRKACAPIM1
SCHEMBL2574444 0.78 BRD4 (0.44) BRD4DYRK1ACDC7PRKACAPIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9181246-B2 Pyrrolopyridine inhibitors of kinases ABBVIE INC. (US) 2015-11-10 US disclosed
US-20140357616-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBVIE INC (US) 2014-12-04 US disclosed
US-8822446-B2 Pyrrolopyridine inhibitors of kinases ABBVIE INC. (US) 2014-09-02 US disclosed
US-20110257152-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2011-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140357616-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES CDC7, MAP3K7, CDK1 BRD4 1274/4885DYRK1A 355/4885CDC7 1/4885
US-20110257152-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES CDC7, MAP3K7, CDK1 BRD4 1274/4885DYRK1A 355/4885CDC7 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.